📇 Rhumatologue · CAEN · (14) · Libéral

MME ANNE MOREAU

Pourquoi vous devez consulter ce praticien

3 raisons identifiées

Auteur de référence en rhumatologie
23 articles scientifiques publiés — un praticien à la pointe de la recherche
Expérience confirmée
35 ans d'exercice en rhumatologie — recul clinique solide
Délais de RDV courts dans la région
150.8 rhumatos / 100 000 hab. — département bien doté

Rhumatologue

📍 CAEN (14)LibéralRPPS 10002113099

Expérience confirmée

35ans d'exercice (thèse 1991)

📊 Reconnaissance scientifique : 20/100📝 72 articles publiés🇫🇷 Publications académiques françaises (8)

✨ Génération du profil synthétique IA en cours…

Thèses universitaires

Données ANS publiques (Licence Ouverte 2.0) · Enrichissements MonRhumato 100 % opt-in · Toute personne référencée peut demander la suppression ou la rectification.

Top publications · les plus citées

Nationwide incidence of sarcomas and connective tissue tumors of intermediate malignancy over four years using an expert pathology review network

PloS one · 2021

📚 213 citations🎯 RCR 16.62Top 1% NIH🔓 Open Access

Lire l'abstract Crossref ↓

Background Since 2010, nationwide networks of reference centers for sarcomas (RREPS/NETSARC/RESOS) collected and prospectively reviewed all cases of sarcomas and connective tumors of intermediate malignancy (TIM) in France. Methods The nationwide incidence of sarcoma or TIM (2013–2016) was measured using the 2013 WHO classification and confirmed by a second independent review by expert pathologists. Simple clinical characteristics, yearly variations and correlation of incidence with published clinical trials are presented and analyzed. Results Over 150 different histological subtypes are reported from the 25172 patients with sarcomas (n = 18712, 74,3%) or TIM (n = 6460, 25.7%), with n = 5838, n = 6153, n = 6654, and n = 6527 yearly cases from 2013 to 2016. Over these 4 years, the yearly incidence of sarcomas and TIM was therefore 70.7 and 24.4 respectively, with a combined incidence of 95.1/10 6 /year, higher than previously reported. GIST, liposarcoma, leiomyosarcomas, undifferentiated sarcomas represented 13%, 13%, 11% and 11% of tumors. Only GIST, as a single entity had a yearly incidence above 10/10 6 /year. There were respectively 30, 64 and 66 different histological subtypes of sarcomas or TIM with an incidence ranging from 10 to 1/10 6 , 1–0.1/10 6 , or < 0.1/10 6 /year respectively. The 2 latter incidence groups represented 21% of the patients with 130 histotypes. Published phase III and phase II clinical trials (p<10 −6 ) are significantly higher with sarcomas subtypes with an incidence above 1/10 6 per. Conclusions This nationwide registry of sarcoma patients, with exhaustive histology review by sarcoma experts, shows that the incidence of sarcoma and TIM is higher than reported, and that tumors with a very low incidence (1<10 6 /year) are less likely to be included in clinical trials.

Progression of disease within 2 years (POD24) is a clinically relevant endpoint to identify high-risk follicular lymphoma patients in real life

Annals of hematology · 2020

📚 44 citations🎯 RCR 2.00

A phase 2 study of rituximab, bendamustine, bortezomib and dexamethasone for first-line treatment of older patients with mantle cell lymphoma

Haematologica · 2019

📚 36 citations🎯 RCR 1.46🩺 Clinique🔓 Open Access📄 PDF gratuit ↗

Cookies & analyse de trafic

MME ANNE MOREAU

Pourquoi vous devez consulter ce praticien

Thèses universitaires

Activité de recherche & publications

Publications académiques en France

Lieu de consultation

Tarifs & secteur de conventionnement

Prendre rendez-vous & contact

Top publications · les plus citées

Publications scientifiques (23) — classées par pathologie

Transversal13

Biothérapies non-anti-TNF4

Épidémiologie & registres2

Essai clinique1

Génétique1

Lupus1

Revue générale1

Vascularites1

Datasets & protocoles partagés

Partager cette fiche